10:04 AM EST - Medicenna Therapeutics Corp. : Announced today that it will present pre-clinical data on MDNA11 and IL-2 Superkines in glioblastoma models at the 29th Annual Meeting of the Society of Neuro-Oncology taking place in Houston, Texas from November 21 – 24. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.09 at $1.85.
